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Abstract 
Background: Dental caries is one of the most prevalent non-communicable disease globally and can have serious 
health sequelae impacting negatively on quality of life. In the UK most adults experience dental caries during their 
lifetime and the 2009 Adult Dental Health Survey reported that 85% of adults have at least one dental restoration. 
Conservative removal of tooth tissue for both primary and secondary caries reduces the risk of failure due to tooth-
restoration, complex fracture as well as remaining tooth surfaces being less vulnerable to further caries. However, 
despite its prevalence there is no consensus on how much caries to remove prior to placing a restoration to achieve 
optimal outcomes. Evidence for selective compared to complete or near-complete caries removal suggests there 
may be benefits for selective removal in sustaining tooth vitality, therefore avoiding abscess formation and pain, so 
eliminating the need for more complex and costly treatment or eventual tooth loss. However, the evidence is of low 
scientific quality and mainly gleaned from studies in primary teeth.
Method: This is a pragmatic, multi-centre, two-arm patient randomised controlled clinical trial including an internal 
pilot set in primary dental care in Scotland and England. Dental health professionals will recruit 623 participants over 
12-years of age with deep carious lesions in their permanent posterior teeth. Participants will have a single tooth 
randomised to either the selective caries removal or complete caries removal treatment arm. Baseline measures and 
outcome data (during the 3-year follow-up period) will be assessed through clinical examination, patient question-
naires and NHS databases. A mixed-method process evaluation will complement the clinical and economic outcome 
evaluation and examine implementation, mechanisms of impact and context. The primary outcome at three years 
is sustained tooth vitality. The primary economic outcome is net benefit modelled over a lifetime horizon. Clinical 
secondary outcomes include pulp exposure, progession of caries, restoration failure; as well as patient-centred and 
economic outcomes.
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Background
Dental caries in permanent teeth is a widespread and 
costly public health problem. Globally, it is one of the 
most prevalent non-communicable disease and can have 
serious health sequelae which can impact negatively on 
quality of life and productivity[1–5]. In the UK most 
adults experience dental caries during their lifetime and 
the 2009 Adult Dental Health Survey reported that 85% 
of adults have at least one restoration [6]. The removal of 
less tooth tissue for both primary and secondary caries 
reduces the risk of failure due to tooth-restoration frac-
ture, complex fracture and the surfaces are less vulner-
able to further caries [7]. Furthermore, smaller cavities 
simplify the operative procedure when placing restora-
tions, so improving their long-term viability.
However, despite the prevalence of this non- commu-
nicable disease there is no consensus about how much 
caries affected tooth tissue to remove prior to placing a 
filling to achieve optimal patient outcomes. Evidence for 
selective compared to complete or near-complete car-
ies removal suggests there may be benefits for selective 
removal in sustaining tooth vitality therefore avoiding 
abscess formation and pain, and eliminating the need for 
more complex, costly treatment or eventual tooth loss. 
However, the evidence is of low scientific quality and 
mainly gleaned from studies on primary teeth.
The majority of current NHS treatment is manag-
ing failed restorations and their consequences mov-
ing to increasingly invasive and costly treatments. NHS 
expenditure on primary and secondary dental care in 
England approximates to £3.4bn per year, with over one 
million patient contacts weekly. Many of these contacts 
relate to treatment of caries. In 2016/17 in England, there 
were over 7m permanent fillings, over 2m extractions 
and around 1.5 m endodontic treatments, crowns, inlays 
or bridges provided to adult NHS patients in primary 
dental care. The total value of these treatments was about 
£1.27  bn, with a significant burden on both patients 
(~£635 m) and the NHS (~£639–£290 m for fee-paying 
and a further £349 m for exempt patients) [8] . A similar 
pattern of spend has been observed in Scotland for 2017 
[9]. This does not take into account the dental treatment 
provided in private practice or the costs of NHS treat-
ments delivered in secondary care.
The importance of this topic has been highlighted 
both by patients and general dental practitioners. Gen-
eral dental practitioners within the Scottish Dental Prac-
tice Based Research Network (http:// www. sdpbrn. org. 
uk/) in 2011 voted this as the top research priority. More 
recently, focus groups and interviews with general den-
tal practitioners followed by a national online survey of 
dental practitioners, which was conducted as part of this 
proposal, have established the current importance of the 
topic and informed the trial design of SCRIPT. The 320 
survey participants demonstrated considerable variation 
in practice with 3% reporting they always perform selec-
tive caries removal and 13% reporting they never perform 
selective carious tissue removal. The primary outcome 
in the SCRIPT trial was considered to be important by 
99% of participants and their free text comments clearly 
demonstrate the current professional uncertainty around 
how best to manage patients with deep carious lesions—
“would be willing to use selective caries removal if there 
was proof it does no harm” and “I’d be very keen to see 
more research in this area and would put it to use in my 
day to day practice.”
In this trial, in addition to adults, young peo-
ple between the ages of 12  years and 15  years will be 
included because the 2013 UK child dental health sur-
vey reported that nearly a half (46%) of 15 year olds and 
a third (34%) of 12-year-olds had "obvious decay experi-
ence" in their permanent  teeth12. Of these a fifth (19%) 
of 12-year-olds and 15-year-olds (21%) had decay into 
dentine requiring treatment. Toothache was experienced 
by 18% of 12-year-olds and 15% of 15-year-olds. This sug-
gests that the burden of dental caries is very high in this 
group and therefore including this age group in the trial 
would generate evidence of acceptability and potential 
Discussion: SCRiPT will provide evidence for the most clinically effective and cost-beneficial approach to manag-
ing deep carious lesions in permanent posterior teeth in primary care. This will support general dental practitioners, 
patients and policy makers in decision making.
Trial Registration Trial registry: ISRCTN. Trial registration number: ISRCTN76503940. Date of Registration: 30.10.2019. URL 
of trial registry record: https:// www. isrctn. com/ ISRCT N7650 3940?q= ISRCT N7650 3940% 20& filte rs= & sort= & offset= 1& 
total Resul ts= 1& page= 1& pageS ize= 10& searc hType= basic- search.
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issues related to actual treatment provision. Such evi-
dence would help the dental practitioners in primary care 
to adopt minimally invasive approaches to carious tissue 
removal especially when the recent EU directive has rec-
ommended not to use amalgam fillings in under 15-year-
olds [10].
This was further highlighted by a research priority set-
ting exercise conducted with patients at a general den-
tal practice in Derbyshire with the greatest potential 
benefit seen for the young people. A Patient and Public 
Involvement (PPI) group at the Health Services Research 
Unit (HSRU) in Aberdeen felt that development of such 
conservative techniques was very important as they 
could improve both the health and dental experience of 
patients. Overall, new evidence investigating whether 
a procedure involving sealing in decay in reduces the 
chances of teeth being lost and reduces the chance of 
painful episodes and further complex treatment like root 
canal treatment would be important and welcomed by 
patients.
Randomised controlled clinical trials and systematic 
reviews have concluded that selective caries removal 
(SCR) may offer benefits, but the evidence on manag-
ing deep caries in permanent teeth is weak and biased 
[11–14]. Schwendicke et al. [11] found a significant risk 
reduction for pulp exposure (OR 0.31 [0.19–0.49]), but 
pulp symptoms (OR 0.58 [0.31–1.10]) and risk of resto-
ration failure (OR 0.97 [0.64–1.46]) were inconclusive 
(n=1,257). Similarly, for selective caries removal, Rick-
etts et al. [14] found a significant risk reduction for pulp 
exposure (OR 0.23 [0.08–0.69]), but again pulp symptoms 
(OR 0.27 [0.05–1.60]) and risk of failure were inconclu-
sive (n=345 in the partial caries analysis of primary and 
permanent teeth). Quality of the evidence is judged to be 
poor scientifically and most of the included studies were 
conducted solely on children with short term follow-up 
[15–17], used less durable materials [16, 18] or included 
more aggressive complete caries removal (CCR) inter-
ventions to “hard” dentine [13, 19] than would be present 
in UK NHS.
Bjørndal et  al. [12] followed-up for 5 years a 2-staged 
(stepwise) carious tissue removal protocol on lesions 
spreading into the pulpal quarter of dentine (n=239). 
Pulp exposure rate was lower in this stepwise removal 
protocol (21.2% vs. 35.5%; p = 0.014) and more successful 
(60.2% vs 46.3%) (p = 0.031) when pulp exposures were 
classed as failure. The trial has limited generalizability to 
SCRIPT’s context and patients: it recruited participants 
with more severe caries and its two interventions dif-
fered from SCRIPT’s. Their partial approach (2-step) was 
similar to CCR; their CCR approach was more aggressive 
than the one we propose to use, excavating “hard” den-
tine. Therefore, more evidence is needed about the per-
formance of a minimally invasive option of SCR in the 
NHS and about whether dentists will adopt it. There is 
one ongoing trial in France [20] looking at this research 
question in a secondary care setting. Personal commu-
nication with the trial team confirmed they had experi-
enced a merger (contamination) of the two technologies 
(i.e. the two techniques undertaken by an individual den-
tist tended to become more similar dependent upon their 
initial skills and preferences). The trial has had more than 
30% loss to follow-up. The authors believe that is due 
to the secondary care setting where patients are usually 
transient and short term. Our research robustly monitors 
and minimises the risk of the technologies merging, and 
most patient participants are routine attenders at their 
dental practice.
Therefore, this research is important to establish 
whether SCR will sustain tooth vitality and reduce the 
need for complex, costly treatment including root canal 
treatment, crowns, extractions, bridgework or implants 
[21]. In addition to potential cost savings, this reduced 
treatment need would be expected to improve quality of 
life and reduce anxiety and stress.
The risk to participants is low as both treatments are 
utilised in NHS practice albeit that SCR is relatively 
under-employed. For SCR, which is a minimally invasive 
treatment, the perceived risk is the residual caries alone 
may lead to further deterioration of the tooth. The risks 
from CCR are already managed within existing dental 
practice so the trial does not impose any new risks. Risk 
in both arms will be monitored as part of the trial as the 
primary and some secondary outcomes directly measure 
the impact of each treatment.
Methods/design
This is a pragmatic, primary dental care, multi-centre, 
single-masked, two-arm patient randomised controlld 
trial including an internal pilot, comparing the clini-
cal-effectiveness and cost–benefit of Selective Caries 
Removal (SCR) with Complete Caries Removal (CCR) in 
permanent posterior teeth in participants aged 12 years 
and over.
Follow-up will last at least 3  years and will be con-
ducted in multiple sites across the UK. The design 
includes an internal pilot to assess the recruitment of 
practices and participants and monitor compliance with 
the clinical protocol and acceptability for patients and cli-
nicians (Fig. 1).
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Objectives
Primary objective
To compare clinical effectiveness and cost-benefit (mod-
elled over a lifetime horizon) of selective caries removal 
(SCR) with complete caries removal (CCR) in perma-
nent teeth in NHS dental attenders aged 12 years and 
over who have deep caries in an adult pre-molar or molar 
tooth.
Secondary objectives
• To evaluate pulp exposure during caries removal, 
progression of caries, dental pain and need for dental 
pain relief, restoration failure and patient oral health-
related quality of life.
• To determine general population preferences for the 
type of treatment provided and outcomes of care and 
predict general population barriers to its uptake. To 
estimate NHS and patient perspective costs, incre-
mental net benefit (willingness to pay minus costs) 
over three year follow up and incremental cost per 
Fig. 1 A flow diagram illustrating the SCRiPT Trial design. *The study is statistically powered so that up to 25% of participants in total could receive 
the non-allocated procedure. Processes are in place to minimise this from occurring
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Quality Adjusted Life Year (QALY) gained over the 
three year follow-up and a modelled lifetime horizon.
• To explore the implementation of technologies and 
the mechanisms of impact including acceptability
Interventions
The interventions being evaluated, SCR and CCR, dif-
fer solely in the amount of carious dentine removed 
during the excavation phase of restorative treatment of 
deep dental caries. Clinicians will restore the tooth with 
the material that they would normally use. This may be 
amalgam or resin composite with or without glass iono-
mer cement. Placement of a separate pulp lining pro-
tection material is permitted. However, it should not be 
medicated i.e. including steroids or antibiotics. Informa-
tion about any pulp protection material placed will be 
recorded.
Intervention: selective caries removal (SCR)
• Gain access to the dentine caries by removing super-
ficial enamel or existing restoration
• Remove caries from the periphery of the cavity to 
allow for good adaptation and seal to the restoration
• Either at the enamel dentine junction or the periph-
eral 2 mm of dentine if the cavity margin is on root 
dentine. Remove remaining carious dentine to soft 
dentine “that deforms when an instrument is pressed 
into it and can be easily scooped up (e.g. with a spoon 
hand excavator) with little force being required” [22]
Control: complete caries removal (CCR)
• Gain access to the dentine caries by removing enamel 
or existing restoration
• Remove caries to firm dentine “physically resistant 
to hand excavation and some pressure needs to be 
exerted through an instrument to lift it” [22]
Training in the delivery of intervention
As the primary difference between the health technolo-
gies being assessed is the amount of carious dentine 
removed effective clinical training is of prime impor-
tance. The training will utilise a novel clinical learning 
tool, providing an on demand online resource and mech-
anisms for monitoring sustained delivery of the allocated 
technology.
All clinicians will participate in and complete the 
SCRiPT trial training (Part 1 hands-on in clinical 
procedures Part 2 Good Clinical Practice). Other mem-
bers of the dental team will complete SCRIPT Part 2 
which can be delivered remotely. Prior to the COVID-19 
pandemic Part 1 training was provided in its entirety at 
hands-on clinical facilities. This included information on 
the background of operative caries management and trial 
interventions, together with hands on practice of both 
SCR and CCR on plastic teeth that have been 3D printed 
at different densities to replicate caries.
During the COVID-19 pandemic Part 1 training was 
re-designed to meet physical distancing guidelines by 
using a blended learning approach i.e. a combination of 
virtual theoretical training and a remote practical train-
ing exercise. Part 1 training was divided into part 1a and 
1b. Part 1a covers the background to the interventions 
and description of the interventions, including video 
recordings of the interventions. This training was/is 
delivered remotely via Zoom meetings. Part 2a involves 
posting 3D plastic teeth to the dentists to complete the 
trial interventions and returning a selected pair of teeth 
to the trial clinical team for validation and to check 
adherence to protocol. In cases where further training 
was required this was followed up by individual zoom 
discussion, feedback and further practice on 3D printed 
teeth.
Monitoring fidelity to protocol
Monitoring fidelity with the clinical protocol is essential 
to exclude merger of the clinical techniques and consist-
ency of technology used when more than one tooth has 
a deep carious lesion. We will implement 3 strategies to 
assess compliance:
• Clinicians will be asked after every third patient 
to cut both a SCR and CCR cavity in two 3D com-
puter generated sample teeth and return these to the 
research office. These teeth will be examined by a 
member of the clinical team to monitor compliance. 
If merger of SCR and CCR is observed additional 
training and or reinforcement of protocol will be pro-
vided
• The CRF will include an assessment of colour, hard-
ness and consistency to monitor whether SCR or 
CCR has been performed according to protocol. The 
lighter shade would be consistent with CCR, a darker 
shade with SCR. The hardness of the cavity will be 
assessed with a dental explorer/spoon excavator. Soft 
would indicate SCR and hard would indicate CCR. 
The CRFs will be assessed in real time to monitor 
fidelity and feedback will be provided if evidence of 
merger is observed.
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• Baseline and 1-year follow-up bitewing radiographs 
will be assessed by a researcher masked to treatment 
group, to confirm the extent of initial caries and fol-
lowing the restoration the presence of caries. Follow 
up x-rays will be taken at intervals judged appropri-




General dental practice is the main provider of NHS den-
tal care. SCRIPT will recruit approximately 65 NHS den-
tal practices (and up to 75 clinicians) from across the UK 
within the participating regions. A list of study sites will 
be available on the study website.
An open invitation will be distributed using routine 
NHS communication systems such as NHS Education 
for Scotland’s Portal, BDA section and Local Dental 
Committee networks to request expressions of interest. 
Practices that have successfully recruited to and deliv-
ered previous dental HTA trials will be targeted through 
our research networks. Also, the planned NIHR Clini-
cal Research Network oral and dental specialty national 
questionnaire will be used to identify interested prac-
tices. Following the expression of interest, a trial brief-
ing session will be delivered remotely, and an appraisal 
of each practice’s ability to recruit participants will be 
conducted.
Identifying and recruiting participants
The trial will aim to recruit 65 practices (each recruit-
ing an average of 10 participants) to achieve the target of 
623 participants. Trial clinicians will identify patients at 
routine visits that meet the inclusion criteria and explain 
the trial. Eligible patients who express interest will be 
given a participant information leaflet (Additional file 1) 
and an appointment for their treatment as per current 
clinical practice. At the treatment visit the patient will 
be given the opportunity to clarify any questions prior to 
informed consent being obtained and recorded on a writ-
ten consent form (Additional file 2).
The eligibility of all participants will be assessed and 
determined by their dental practitioner following clini-
cal and radiographic examination according to pre-
determined criteria. Those who do not wish to take part 
will receive caries removal and restoration as per cur-
rent practice. Those who are eligible and wish to take 
part will give informed consent to the clinician providing 
treatment.
A baseline questionnaire will be completed by the par-
ticipant to collect baseline patient centered outcomes. 
Randomisation will then take place using an online 
randomisation system. If the participant has more than 
one eligible tooth, a trial tooth will be selected at random 
by the randomisation application. The randomisation 
algorithm will use recruitment site, number of eligible 
teeth (1; > 1) and type of caries (primary and secondary) 
as minimisation covariates to allocate to treatment inter-
vention and control groups in a ratio of 1:1To maintain 
participant blinding, participants will not be informed of 
their allocated treatment group following randomisation. 
Baseline clinical information will be recorded by the cli-
nician after the treatment has been provided.
After the initial intervention participants will receive 
any treatment deemed clinically appropriate by their 
dentist as per normal practice.
Inclusion criteria
• Aged 12  years and over, suitable to receive either 
clinical procedure.
• Patients able to provide informed consent
• Patients receive some or all of their treatment under 
NHS
• One (or more) pre-molar or molar teeth with car-
ies (primary or secondary) extending into the pulpal 
third of dentine.
• Caries may be proximal and/or occlusal and the 
lesion will be suitable for a direct filling with a single 
restoration.
Exclusion criteria
• If the carious tooth shows signs or symptoms of irre-
versible pulp pathology or loss of vitality including:
• The presence of a sinus








• Sustained tooth vitality
Economic
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• Pulp exposure during caries removal;
• Progression of caries;
• Tooth restoration failure and re-restoration
Patient-centered
• Dental pain; need for dental pain relief;
• Health status; Oral Health-Related Quality of Life
• Oral health behaviours
• Patient satisfaction
Economic
• General population preferences,
• Willingness to pay
• NHS and patient perspective costs collected over 
three years follow up, and modelled over a lifetime 
horizon
• QALYs and incremental cost per QALY over three 
years follow up, and modelled over a lifetime horizon
• Incremental net benefits over three years follow-up
Data collection and processing
Participating dental practices will be expected to main-
tain a file of essential trial documentation which will 
be provided by the Trial Coordinating Office Dundee 
(TCOD).
Participants who lose capacity to consent during the 
study will be withdrawn. Identifiable data already col-
lected with consent would be retained and used in the 
study. No further data will be collected or any other 
research procedures carried out on or in relation to the 
participant.
Baseline characteristics
At baseline information will be collected on partici-
pants’ socio-demographic characteristics, generic health-
related quality of life, oral health-related quality of life, 
oral health behaviours, and time and travel costs through 
a participant questionnaire. Oral health status and car-
ies experience (DMFT) will be calculated by the clini-
cian. Bitewing radiographs and periapical radiographs (if 
clinically needed) will be collected as part of routine care 
but copies will be provided to the trial team to provide 
a measure of the extent of caries and confirm exclusion 
of signs of pulp pathology. A case report form (CRF) will 
record the details of treatment including caries removal, 
restoration placed, and resources required to deliver the 
respective treatments. Any modification of or deviation 
from the intervention will be recorded on the CRF to 
inform the clinical outcomes.
Clinical outcomes
Clinical outcomes will be recorded on the CRF com-
pleted by the clinician at the end of each course of treat-
ment until the end of the trial. It will record clinical and 
participant-reported signs and symptoms of tooth pain, 
the findings of any radiographs taken, the reason for 
and detail of any dental treatment provided for included 
teeth. Radiographs taken during the trial will be taken 
according to good practice guidelines based on caries 
risk at intervals between 6 and 24 months. Clinicians will 
take a bitewing radiograph at one year post-treatment, 
in accordance with Faculty of General Dental Practition-
ers (FGDP) guidelines [23] since included patients are 
considered at high caries risk, at the follow-up visit and 
the trial team will request a copy for treatment adher-
ence monitoring. If a participant has not received any 
post-intervention visit by 4  months before the end of 
the follow-up period, they will be contacted by the den-
tal practice and offered an appointment. All radiographs 
will be assessed by a clinical researcher who is blinded 
to treatment allocation. Digital radiographs will be for-
warded via the secure trial management system and digi-
tal images of wet films made.
Sustained tooth vitality will be collected at routine 
dental visits, recorded in the CRF and used in a time- to-
event framework defined as the time from randomisation 
to root canal treatment or extraction due to loss of vital-
ity, the primary time point of interest is three years. Sus-
tained tooth vitality will be determined by the absence of 
root canal treatment or extraction due to loss of vitality 
and the absence of clinical signs and symptoms of pulp 
death including evidence from radiographs.
Pulp exposure during caries removal will be recorded 
by the clinician at the time of intervention. If soft tissue 
within the tooth is exposed this will be detected visually 
by bleeding and or a pink or red spot.
Progression of caries will be clinically and radio-
graphically assessed by the clinician at each visit as per 
national guidelines. An independent blinded assessor will 
also evaluate the radiolucent area on radiographs taken 
between baseline and follow-up.
Tooth restoration failure and re-restoration will 
include the reason and subsequent treatment and will be 
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collected at routine visits in a similar fashion to the pri-
mary outcome.
Participant reported outcomes
Patient focused outcomes will be recorded pre-randomi-
sation at the baseline visit and on an annual postal or 
online follow-up questionnaire until 3-years post-ran-
domisation (except when indicated otherwise).
Dental pain and need for dental pain relief will be 
recorded on the annual patient questionnaire. Dental 
pain will be measured using a Numerical Pain Rating 
Scale (NPRS) [24]. Health status will be assessed using 
the generic EQ-5D-5L, consisting of five dimensions 
of Health-Related Quality of Life (HRQoL) [25]. Oral 
Health Related Quality of Life will be assessed using the 
Oral Health Impact Profile 14 (OHIP-14). OHIP-14 is the 
most commonly used validated oral HRQoL measure and 
has been used successfully in previous HTA trials [26]. 
Oral Health behaviours will be assessed at baseline and 
3-years post-randomisation using questions about type of 
toothbrush, brushing twice a day for 2 min, frequency of 
interdental cleaning and behaviour after brushing.
Outcomes from data linkage with routine administrative 
NHS health records
Dataset: Management Information and Dental Account-
ing System (MIDAS) [27] collated information on all 
child and adult primary care dental practice appoint-
ments and treatments in Scotland (including Childsmile 
practice prevention items).
Trial participant data will be linked to individual health 
records from MIDAS database, tooth-specific data on 
specific treatments (restorations, root canal therapy, and 
extractions).
Economic outcomes
NHS perspective costs will be collected using a combina-
tion of clinician reported data using CRFs (for the costs 
of intervention delivery and caries treatment provided), 
data linkage to routinely collected dental claims (includ-
ing tooth level data where possible) from the respective 
countries (ISD in Scotland, NHS BSA in England) and 
participant reported contact with non-dental NHS ser-
vices for problems related to their teeth. Participant per-
spective costs will be obtained from NHS claims data (for 
treatment co-charges) and through self-reported infor-
mation through participant completed questionnaires in 
practice and annually. Time, travel and lost productivity 
costs associated with required dental care will be col-
lected through a questionnaire with a sample of respond-
ents, collected in the first or second annual questionnaire. 
EQ-5D-5L data from annual questionnaires will be used 
to calculate QALYs.
General population preferences will be obtained from 
a discrete choice experiment (DCE with an online repre-
sentative sample of the UK general population. The DCE 
will be used to elicit willingness to pay (WTP) for SCR, 
CCR and patient relevant short and longer term out-
comes (e.g. need for further treatment). The DCE will be 
used to predict intervention uptake.
Process evaluation
A mixed-method process evaluation will complement the 
outcome evaluation and examine implementation, mech-
anisms of impact and context as per MRC guidance [25]:
Implementation
The process through which the intervention (SCR or 
CCR) is delivered in dental practices, what is delivered in 
different practices and by whom, the fidelity and adapta-
tion of the protocol and the resources used.
Mechanisms of impact
How the intervention is received by patients (acceptabil-
ity) and how clinician/patient interactions trigger change 
in approaches to caries removal and placement of resto-
rations and any unintended effects.
Context
Through examining how external factors including den-
tal contracts and the use of skill mix influence the deliv-
ery of the intervention and its outcomes. The process 
evaluation will include the self-report questionnaires as 
described above, analysis of trial outcomes data (includ-
ing CRFs) and qualitative interviews with patients, dental 
professionals and other stakeholders such as managers of 
corporate bodies and dental service commissioners.
Process evaluation: qualitative interviews—SCRiPT 
participants
A sample of SCRiPT participants will be interviewed 
to explore their experiences of the intervention. A pur-
posive sample will be used to ensure a range of partici-
pants in terms of age, patterns of dental attendance and 
tooth vitality or not. Potential participants for interview 
will be identified by the research team and they will be 
sent a letter of invitation along with a participant infor-
mation sheet about the interview. Those who are willing 
to take part in the interview will return an expression of 
interest form to the research team. If they expressed an 
interest in being interviewed, they will then be contacted 
by the researcher to arrange a suitable time and location 
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to hold the interview. Before the start of each interview 
the researcher will obtain informed consent. Recruit-
ment will continue until no new themes emerge. Previous 
similar studies have involved 10–15 patients in qualita-
tive interviews [25]. The interviews will be guided by the 
concept of patient acceptability using a topic guide devel-
oped by the research team. The interviews will be audio-
recorded and transcribed verbatim by a professional 
transcription service who will be approved as vendors by 
the sponsor. The data will be analysed using framework 
analysis as it provides a pragmatic approach which pro-
duces results that can be easily incorporated into mixed-
method studies, process evaluations and RCTs [28–30] 
(see details below).
Process evaluation: qualitative interviews—dental 
stakeholders
A sample of dental stakeholders will be interviewed dur-
ing the set-up phase to explore their views about the 
usual care they provide and how they envisage deliver-
ing the intervention, and during the trial to explore their 
experiences of delivering the intervention within their 
own setting. Individual stakeholders may take part in one 
or two interviews and may be interviewed at both time 
points to consider experiences of the trial in relation to 
expectations. Dental stakeholders will be purposively 
sampled based on role, geographical location, the types 
of dental contract they are working under, previous expe-
rience of differing restorative techniques and, for inter-
views carried out once sites have opened, their levels of 
engagement with the trial. Potential stakeholder partici-
pants will be selected, with dental professionals selected 
from the list of all practices involved in SCRiPT. The 
sample will include those who had recorded instances of 
having deviated from the clinical protocol for a variety of 
reasons, as these cases are of particular interest. Recruit-
ment will continue until no new themes emerge. Previ-
ous similar studies have involved 25–30 stakeholders 
in qualitative interviews [31]. Potential participants for 
interview will be identified by the research team and they 
will be sent a letter of invitation along with a participant 
information sheet about the interviews. Before the start 
of each stakeholder’s first and any subsequent interview 
the researcher will obtain and record informed consent 
using appropriate method, e.g. verbal, written, digital.
The interviews will be guided by the theoretical 
domains framework (TDF) [32] which has been used 
previously in implementation research to understand 
the motivations, cognitions and behaviours of dental 
professionals when implementing evidence-based prac-
tice [31–33]. A topic guide based on the TDF has been 
developed by the research team. The interviews will be 
audio-recorded and transcribed verbatim by a profes-
sional transcription service who will be approved as ven-
dors by the sponsor. Framework analysis based on the 
TDF will be used.
The analysis will involve the following stages: identify-
ing initial themes, labelling the data, sorting the data by 
theme and synthesising the data. The analysis will be con-
ducted by an experienced research associate with sup-
port from grant-holders. In addition, during the analysis, 
regular meetings will be held between the research team 
to discuss the emergent themes and consider the implica-
tions of these for the implementation and delivery of the 
intervention.
Scheduling of events
Data will be collected as detailed in Table 1.
Study within a trial
Poor retention of participants recruited to clinical trials is 
a known problem which can reduce statistical power, bias 
estimates of intervention effects and reduce the credibil-
ity of trial results [34]. SCRiPT will investigate whether 
giving participants a welcome letter on entry to the trial 
improves questionnaire response rates and retention 
across the trial’s follow-up. The letter will welcome par-
ticipants to the trial, reiterate the participant journey 
(summarising information provided in the patient infor-
mation leaflet), identify the location of the participant’s 
study tooth and list the expectations for participation i.e. 
the need to return the trial questionnaires. Allocation to 
receive or not receive the letter will be randomised fol-
lowing recruitment into the trial by the trial office and 
will be 1:1. The intervention group will be issued with a 
letter within 2 months of consent to participate. The con-
trol group will not be issued with a letter.
Analysis plan
Sample size calculation
The sample size calculation is event-based. We aim to 
detect an absolute improvement in sustained tooth vital-
ity at three years of 12% from 80% (CCR) to 92% (SCR). 
The control rate of 80% is based upon the existing evi-
dence base, clinical experience and confirmed by Scot-
tish tooth-level routine data. As described in Sect.  2.1 
above, the current evidence base gives rates of pulpal 
exposure that are higher than those seen in UK NHS 
and therefore our rate of sustained tooth vitality will be 
higher than observed in those studies. Bjørndal 2017 [12] 
presented a tooth vitality rate of approximately 80% at 
3  years for two-step selective restoration in lesions that 
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were deeper than those in this trial. The two-step proce-
dure is more similar to a CCR than the SCR in our trial. 
The Scottish tooth specific data demonstrated that of 
459,648 teeth that required a three surface restoration 
in 2013, 6.6% had received further endodontic treatment 
or were extracted at 3 years follow-up. These teeth how-
ever, could be at any level of dentine involvement and 
it is not possible to identify the level of involvement in 
the routine data. Therefore, as the study is interested in 
only teeth with involvement in the pulpal third of den-
tine, it has been estimated that the number of events may 
be three times larger. There is little empirical evidence 
to inform the expected size of an important effect. A 
target difference of 12% was judged clinically important 
and plausible by both dentists and PPI partners. The 
target difference of 12% was also informed by the differ-
ence observed in Bjørndal 2017 [12] which was 13.7% 
at 5  years. However, as this is a patient RCT there are 
concerns around contamination (participants receive 
the intervention that they were not randomly allocated 
to). The team conservatively have allowed for up to 25% 
contamination and therefore the sample size for SCRiPT 
aims to detect an absolute improvement of 9%; from 83 
to 92% at three years. Recruitment of 623 participants (71 
events) will detect a hazard ratio of 0.42 between experi-
mental and control strategies and provide, using the 
log-rank test, assuming an exponential failure rate, 90% 
power at a 2-sided 5% significance level. The calculation 
also assumes 17  months of recruitment, a minimum of 
33 months of follow-up and a 30% follow-up attrition at 
the end of year three. Recruitment is assumed to be stag-
gered and builds in seasonal variation. We used the Stata 
package ARTSURV for calculations [35].
Proposed analyses
Demographic and baseline characteristics will be sum-
marised and displayed in tables for all randomised 
patient participants using appropriate summary sta-
tistics. All analyses will initially be performed on an 
Table 1 Scheduling of events
A Costs of time and travel will be collected from a randomly selected subset of participants, across the different annual questionnaire time-points. Each selected 
participant will complete the questions once only
o: Dental Practice-CRF
●: Questionnaire
∇: Data linkage to routine administrative datasets, ongoing over trial duration, at the end of the study, and for longer term follow-up
 ⊕ DCE, administered once online to a nationally representative sample of the UK general population
Screening Baseline (initial 
treatment visit)






Assessment for eligibility o
Informed consent o
Socio-demographic characteristics and eligibility for free 
treatment
o
Clinical status (DMFT) o
Sustained tooth vitality o o o
Pulp exposure during caries removal o
Caries progression dental pain relief o o o
EQ-5D-5L ● ● ●
OHIP-14 ● ● ●
Patient satisfaction • ●
Oral health behaviours ● ●
NHS perspective primary dental care resource use and 
cost
o ∇
NHS perspective use of other NHS services (GP, A&E etc.) o ● ●
Patient perspective unit costs of time and  travelA ●
Patient perspective costs (private care, NHS co-charges 
etc.)
● ● ∇
General population preferences  ⊕ 
Willingness to pay  ⊕ 
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intention -to-treat basis, although use causal methods for 
the analysis of the primary outcome to estimate efficacy 
in the presence of cross- over between treatment arms 
will also be used. Analysis will be fully specified in a Sta-
tistical Analysis Plan.
Primary outcome
The primary endpoint, sustained tooth vitality, will be 
analysed within a time-to-event framework using a Cox 
proportional hazards model, adjusted for minimisation 
covariates and a random effect for clinician included. The 
treatment effect will be summarised by the hazard ratio 
with a 95% confidence interval. The estimated survivor 
function will be graphed.
Secondary outcomes
Secondary clinical time-to-event outcomes (progression 
of caries; tooth restoration failure and re-restoration) will 
be analysed in a similar manner to the primary outcome. 
Pulp exposure will be analysed using logistic regression 
adjusted for minimisation covariates and a random effect 
for clinician included. Secondary outcomes reported by 
participants will be analysed using mixed effects gener-
alised linear models (using the appropriate link function 
for the outcome distribution) for repeated measures. 
Models will make use of data available at all time points, 
adjusted for minimisation covariates, fixed effects for 
treatment and (nominal) time points, and random effects 
for participant and clinician. The primary time point of 
interest will be three years post-randomisation. Treat-
ment effects will be estimated using a treatment-by-time 
interaction and presented with 95% confidence intervals.
Planned subgroup analysis
Subgroup analyses on the primary outcome will explore 
the possible modification of treatment effect by age and 
number of lesions. This will be done by including treat-
ment-by-factor interactions in the model and they will be 
classified as exploratory analyses.
Proposed frequency of analysis
From the internal pilot phase we will report estimates of 
recruitment rates and potentially eligible participants, 
together with appropriate confidence intervals. There are 
no planned interim analyses of the primary or second-
ary outcomes; one final analysis will occur at the end of 
follow-up.
Missing data
Strategies with proven effectiveness in improving reten-
tion will be used to minimise missing data [36]. For 
participants who do not return or are censored early in 
the trial, dental practices will be contacted to find out 
potential reasons for missing data if they are available.
Participants with no event will be censored at their last 
visit with sustained tooth vitality. It is anticipated that a 
small proportion of participants will not return at all, and 
a further proportion will be censored early in the trial 
because they do not come back to their clinician. The 
team will consider how robust the findings are to these 
missing data using multiple imputation approaches under 
an assumption of missing at random, and using pattern 
mixture models if appropriate. In participants with more 
than one eligible tooth, we will repeat our primary analy-
sis with a clustering effect for participant.
Routinely collected data will be considered to supple-
ment missing outcome data if deemed appropriate. We 
will undertake a validation analysis comparing (primary 
outcome) CRF data with routinely collected tooth-level 
data which will also provide the opportunity for second-
ary and economic outcome data analysis if the data are 
valid. This will be detailed in a data linkage analysis plan.
Transfer of data
Data transfer will adhere to the processes detailed in the 
CHaRT Standard Operating Procedure book.
The data will be de-identified before it is securely trans-
ferred. The data will be transferred using ZendTo. This is 
a secure web-based service which can be used to securely 
transfer data between colleagues both inside and outside 
the university. Files are stored on and accessed from the 
University’s secure server, and all files are checked for 
viruses when they are uploaded. The de-identified data 
will be encrypted before it is sent with ZendTo, using 
Office365 AES-256 encryption.
However, sometimes it may be necessary to transfer 
files on CD or USB stick. In such cases, a robust system 
logging the receipt of sent items must be in place either 
for a CD coming into the centre or leaving the centre—
for example, by registered mail or courier, requiring sig-
nature on delivery. As with electronic data, the data on 
the CD/USB stick should be encrypted and password 
protected using an acceptable standard of encryption 
currently available (at least 256-bit encryption).
Data transferred from CHaRT to external parties will 
be subject to approval by the Project Management Group 
using a data request form.
Access to data linked to NHS Scotland routine admin-
istrative data for outcome analysis will be undertaken 
within the NHS Scotland National Safe Haven infrastruc-
ture [37].
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Economic evaluation
A full economic evaluation will be conducted. This will 
include a trial-based analysis at three years follow-up 
and a decision model to assess economic value over an 
extrapolated lifetime horizon. The primary economic 
outcome will be net benefit, WTP minus cost (NHS and 
patient perspective) evaluated in a cost–benefit analy-
sis (CBA) framework, modelled over a lifetime horizon. 
CBA is chosen as the preferred framework because of 
concerns that generic QALY measures are not sufficiently 
sensitive to capture the value of important outcomes in 
dental care. Cost Utility Analysis (CUA) reporting cost 
per QALY will also be conducted as a secondary eco-
nomic analysis to comply with NICE guidelines for tech-
nology appraisal.
Estimation of costs
Routinely collected dental claims data will be used to 
assess the costs to the NHS, and co-charges to patients 
of NHS provided dental treatments. Routine datasets 
will be supplemented with data collected using CRFs in 
the dental practice at each visit. Remaining resource use 
data, NHS and patient perspective costs directly related 
to dental problems will be collected using patient ques-
tionnaires. NHS costs of providing SCR and CCR will be 
based on the appropriate NHS contract-based payments 
to clinicians in the respective UK regions for the base 
case analysis. Contract payments detail the cost burden 
to the NHS but may not capture the full opportunity cost 
of time spent and materials used to deliver the interven-
tions. Therefore, a micro-costing approach will also be 
used as a secondary analysis. Resource use data for the 
intervention micro-costing will include staff resource use 
and time, and consumables with information collected 
in a detailed CRF at the point of intervention delivery. 
Patient perspective costs will include patient co-charges 
for NHS treatments, time and travel costs, time-off work, 
privately purchased care and self-purchased dental care 
products. The participant time and travel cost question-
naire will be sent to a random sample (N = 347) of trial 
participants. The required sample reflects the mini-
mum number of respondents contributing complete 
data that is required to enable a multi-variable regres-
sion to estimate costs according to a range of predictor 
characteristics of the sample. The minimum sample size 
is calculated from the formula N ≥ 50 + 8(k) [38] where 
k is the number of independent categories of the model 
assuming linear additive effects and no interactions. For 
k = 15 explanatory variables in the model, the minimum 
number of fully complete responses to the questionnaire 
is N ≥ 50 + 8(15) ≥ 170. Assuming a questionnaire non-
response rate of 30% and a further item non-response 
rate that would preclude running the model of 30% of 
returned questionnaires (as per the IQuaD study), the 
minimum number of questionnaires that need to be sent 
to obtain the required sample is N = 347 (170/0.7/0.7). 
The questionnaire will be administered to a random 
sample of respondents split across the one and two-year 
annual follow-up time-points. The information col-
lected will also be used to validate an external prediction 
model of time and travel costs that can be used in future 
research. Incremental NHS and patient perspective costs 
for SCR vs CCR will be estimated using generalised linear 
regression models with appropriate specification of dis-
tributions for cost and outcomes data and adjustment for 
baseline covariates.
Estimation of benefits
Willingness to pay (WTP) for the cost–benefit analysis 
(CBA) will be elicited from a discrete choice experiment 
(DCE). The DCE will be conducted with a nationally rep-
resentative sample of the UK general population, using 
online panel surveys. The DCE will explicitly value pref-
erences for provision of SCR and CCR, together with a 
range of plausible outcomes from the trial (e.g. sustained 
tooth vitality, longer term risk of repeat treatments and 
tooth loss). The DCE will examine the trade-offs between 
the potential benefits and risks of different treatment 
strategies. A cost attribute will be included to enable cal-
culation of WTP. The DCE will also be used to assess the 
acceptability of SCR and CCR and predict uptake accord-
ing to patient characteristics (investigating issues of pref-
erence heterogeneity for treatment). The target sample 
size for the DCE (N = 1067) is calculated using Dillman, 
2007 [39], using an estimate of the population of inter-
est (i.e. the UK general adult population) =  ~ 52 mil-
lion), a conservative estimate of variation in the answers 
for the question of interest of 0.5, and an assumed mar-
gin of error of 3% in line with public opinion research, 
with a confidence level of 95%. A further sample of 100 
respondents will be sought for a pilot study of the DCE. 
As a secondary objective, we will measure benefits in 
terms of QALYs gained, based on patient responses to the 
generic EQ-5D-5L health related quality of life measure.
Trial based economic evaluation
Economic evaluations typically take the form of cost-
utility (i.e. cost per QALY). However, in the context of 
dentistry, there are concerns that generic EQ-5D based 
QALYs lack the sensitivity to capture the processes and 
outcomes of care that are of value to patients and deci-
sion makers. Different perspectives of benefits will 
therefore be evaluated (Willingness to pay (WTP) for 
the interventions and outcomes, WTP for dental health 
outcomes only, and Quality Adjusted Life Years (QALYs). 
Costs will be evaluated from an NHS dental, all NHS, 
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and participant perspective. Costs and benefits will be 
combined to estimate incremental net benefit (WTP 
minus costs), incremental net dental health benefit, and 
incremental cost per QALY gained for SCR vs, CCR over 
the three year trial follow up period. Deterministic sen-
sitivity analyses will be undertaken to test the impact of 
assumptions and analysis methods on results. Subgroup 
analysis will be conducted at the region level if data allow 
in order to explore the potential impact of different pay-
ment systems across the UK regions on results. Results 
will be plotted on the cost–benefit and cost-effectiveness 
planes to illustrate the impact of sampling uncertainty on 
results.
Decision modelling
The trial results will be extrapolated over a lifetime hori-
zon using a de novo tooth-level Markov model. The 
model will be built as a cohort model, but we will retain 
the option to move to a more flexible micro-simulation 
model if appropriate. Results will be reported using the 
same net benefit framework as the within trial analysis. 
The final model structure and health state definition (e.g. 
loss of tooth vitality, tooth-restoration-complex failure, 
caries progression, and tooth loss) will be developed in 
conjunction with dental and patient experts. Survival 
analysis methodology will be used to assess the time to 
transition between health states, with survival curves 
fitted over an extended time frame (patient’s life time) 
to extrapolate the time to event data from the trial. The 
survival analysis will be supplemented with data from 
cohort studies and literature reviews to complete popula-
tion of model transition probabilities and relative effects 
as required. Cost data (NHS and patient perspective) 
for health states will be sourced from the trial data and 
routine data sources (PHS / BSA). Benefits in terms of 
WTP will be sourced directly from the DCE for specific 
health states (e.g. WTP to avoid loss of tooth vitality, 
tooth-restoration-complex failure, caries progression or 
tooth loss), together with WTP tariffs from previously 
conducted DCE studies [40]. Sensitivity analyses will 
explore the impact of key assumptions on results. Gaps 
in the evidence base will be identified and their poten-
tial impact on efficiency (net benefit) explored through 
sensitivity analysis. Results will be reported according 
to the same cost and benefit perspectives as detailed for 
the trial-based analysis. Findings will be illustrated using 
cost-effectiveness and cost–benefit acceptability curves. 
A value of information analysis will be undertaken to 
determine the need for future research to resolve any 
residual decision uncertainty and an expected value of 
partial perfect information (EVPPI) analysis will be used 
to prioritise future cost-effectiveness research objectives.
Ethical conduct of the trial
The trial will run under the auspices of the trial office in 
Dundee Dental School and CHaRT in the University of 
Aberdeen. CHaRT is a fully registered Clinical Trials Unit 
with extensive expertise in running multicentre RCTs. 
Both institutions are committed to the highest stand-
ards of research governance and conform to all relevant 
governance guidelines and codes of practice as detailed 
in the Research Governance Framework and ICH guide-
lines for Good Clinical Practice (GCP). Favourable ethi-
cal opinion for the SCRiPT study was confirmed by the 
North of Scotland Research Ethics Committee (REC) on 
the 6th January 2020. The trial will be conducted accord-
ing to the principles of GCP provided by Research Gov-
ernance Guidelines. Annual progress reports, end of 
Trial declaration, and a final report will be submitted to 
the Sponsor and the North of Scotland REC within the 
timelines defined in the regulations.
The CI will ensure, through the TSC and Sponsor that, 
adequate systems are in place for monitoring the qual-
ity of the trial and appropriate expedited and routine 
reports, to a level appropriate to the risk assessment of 
the trial.
A study information leaflet will be given to each poten-
tial participant to inform them of the anticipated risks 
and benefits of taking part in the study. In particular, 
the trade-offs between possible short- term benefits and 
long-term risks will be explained. Informed consent will 
be obtained from the participants in all practices, includ-
ing the parent or guardian of 12–15 year-old participants, 
by an individual who is trained in GCP. Patients will be 
given sufficient time to accept or decline involvement 
and are free to withdraw from the study at any time.
Data protection and archiving
Patients will be reassured that all data which are collected 
during the course of the research will be kept strictly 
confidential. All personal data will be pseudonymised 
and processed in accordance with the General Data Pro-
tection Regulation Act 2018. The relevant research docu-
mentation will be archived at the University of Dundee 
for at least five years after completion of the trial as 
required by the applicable regulatory requirement(s).
Governance arrangements
Research Governance applies to everyone working in the 
Dental Health Services & Research Unit and CHaRT. As 
such, all research will be conducted within the appropri-
ate legislative and regulatory environment and in accord-
ance with GCP. All staff involved in the trial at the two 
centres will have undertaken appropriate GCP training 
(to a level of knowledge that reflects their exposure to the 
principles). The three main groupings that contribute to 
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the governance arrangements for this study are: the Trial 
Management Committee; an independent Trial Steering 
Committee (TSC); and an independent Data Monitor-
ing Committee (DMC). The Trial Steering Committee 
(TSC) includes an independent Chairperson (Professor 
Paul Colthard, Queen Mary University) and other inde-
pendent members (P Duncan, R Ladwa, I Soulsby, C 
Vernazza, H Worthington and P Burns) and will oversee 
the trial. The TSC also comprises a selection of the co- 
applicants including the Principal Investigators (Clark-
son and Ramsay), the trial statistician and the Director 
of CHaRT. There will only be two voting members drawn 
from any of the co-applicants. The TSC will meet annu-
ally throughout the course of the study.
The Data Monitoring and Ethics Committee (DMEC) 
will be chaired by A Maguire and include B Chadwick 
and R Playle. It will meet early in the trial to agree terms 
of reference and other procedures and will likely have 
further meetings at 9, 24 and 36 months. The DMEC will 
report any recommendations to the Chair of the Steering 
Committee.
The University of Dundee has agreed to act as spon-
sor. As such, the TCOD will undertake to communicate 
promptly and effectively with the sponsor to satisfy and 
reassure the sponsor that the sponsor’s obligations on 
the authorisations, the financing and the progress report-
ing (including emerging safety data) of the trial are being 
met. This may include providing comprehensive infor-
mation before the start of a trial for the purposes of risk 
assessment for the sponsor.
All data will be managed in accordance with GDPR 
regulations. Information Governance approval for data 
linkage to NHS Scotland routine administrative datasets 
will be obtained from NHS Scotland Public Benefit and 
Privacy Panel for Health and Social Care.
Arrangements for day‑to‑day management of the trial
The TCOD based in the Dundee Dental School at the 
University of Dundee will provide day to day support 
for the clinical centres and sites. The trial office through 
the trial manager and other administrative positions will 
provide a hub for dissemination of administrative and 
clinical support activities for the trial. The trial manager, 
trial administrator and trial tecretary at the TCOD will 
take responsibility for the day to day collecting, collating, 
handling and entering data for the participant completed 
postal questionnaires, including organising all aspects 
of the questionnaires (mailing, tracking, and enter-
ing returned data using the study web-based data entry 
portal).
CHaRT, Health Services Research Unit, Aberdeen 
University will provide the database applications and IT 
programming for the TCOD, and host the randomisation 
system, co-ordinate the patient follow-up questionnaires, 
provide experienced trial management guidance, and 
take responsibility for all statistical aspects of the trial 
(including interim reports to the TSC and DMEC). The 
PIs (GDPs) will be responsible for recruiting participants 
(including initiating the randomisation) and performing 
all clinical outcome assessment.. An Operations Manage-
ment Group (OMG) led by the Trials Manager, will meet 
weekly in the early stages at the TCOD to ensure smooth 
running of the trial, troubleshooting issues as they arise, 
and ensuring consistency of action across the partici-
pating centres. CHaRT staff in Aberdeen will join this 
group as required, by teleconference.. The study will be 
supervised by a Project Management Group (PMG). The 
co-chairs of this group will be the co-chief investigators 
and will consist of grant holders, representatives from the 
TCOD and CHaRT. The PMG will meet at least monthly 
however meetings may be more frequent. In addition, the 
PMG will also meet at the annual Trial Steering Com-
mittee meeting. A Trial Management Committee will 
meet annually and be chaired by the Principal Investi-
gators and include co-investigators and key members of 
the TCOD and CHaRT. Their remit will be to oversee the 
progress of the trial, and they will report to the independ-
ent TSC.
As a result of the COVID-19 pandemic the trial com-
mittees have moved from face-to-face meetings to tel-
econferencing and will continue to do so in line with 
governmental guidelines.
Safety concerns
SCRiPT involves procedures and treatment which are 
well established in current NHS clinical practice and use. 
In this trial, the following events are anticipated and are 
captured as primary or secondary outcomes rather than 
being captured through adverse event or serious adverse 
event reporting processes.
• failure of tooth vitality with associated signs or symp-
toms (e.g. pain, infection, swelling, periodontitis)
• further treatment required
As this reflects the routine care the trial is designed to 
measure.
In addition, all deaths (any cause) are also recorded by 
the trial office. Events that are serious but are not related 
to caries treatment in the trial tooth will not be recorded 
as SAEs.
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Sponsorship
The University of Dundee is the sponsor of the research. 
The sponsor has had no role in the design of the study 
and will have no role in the collection, analysis, and 




Tayside Medical Science Centre, Ninewells Hospital & 
Medical School.




The study is supported by a grant from the National 
Institute of Health Research (NIHR) Health Technology 
Assessment Program (17/127/07).
Publication
The results of the study will be reported first to study col-
laborators. A main report will be drafted by the project 
management group and circulated to all clinical coordi-
nators for comment before a final version is considered 
for publication by the steering committee.
Dissemination
Any major proposed changes to the protocol will be com-
municated with sponsor, the North of Scotland Research 
Ethics Committee and the HTA.
The findings of the trial will be disseminated widely 
through professional, primary care, public and scien-
tific routes. The results of the trial will be communicated 
directly to all participating dental practices who will be 
invited to attend the SCRiPT conference to showcase 
the results and work done by the practitioners involved. 
The results of the trial will be used to update Cochrane 
reviews and clinical guidelines as published by NICE, 
SIGN and Scottish Dental Clinical Effectiveness Pro-
gramme and the online training resource will be made 
available to learning institutions across the UK. In addi-
tion, it is hoped to produce a range of actionable knowl-
edge tools to encourage implementation of the trial 
results. The cost effectiveness elements of SCRiPT and 
patient related outcomes will be of high importance to 
the NHS policy and decision makers, including the UK’s 
four Chief Dental Officers and as such this trial has the 
potential to impact decision making for the general den-
tal community both nationally and internationally. To 
enable this research to be embedded as an output and 
impact on future decision making we will draw on the 
extensive networks of the research team who are well 
connected, respected and cover a vast number of profes-
sional fields and demonstrate our ability to actively par-
ticipate in creating a Global Evidence Ecosystem for Oral 
Health as aspired to by the MAGIC Project [41]. Many 
of the research team members are part of the academic 
teaching community for both national and international 
undergraduate and postgraduate programmes. Through 
formal and informal channels and established teaching 
community networks, we will actively encourage Den-
tal Schools to embed the research findings and clinical 
implications into teaching.
Milestones for the SCRiPT trial
Dental practice recruitment began at month 3. Patient 
recruitment has been delayed due to the effects of 
COVID-19 and has therefore not commenced on time. 
We predict that patient recruitment will take place 
over an 18-month period. Follow up assessments will 
take place three years after recruitment and delivery of 
intervention.
Discussion
The SCRiPT Trial is an NIHR HTA funded trial being 
undertaken across the UK and will begin to address the 
lack of high-quality evidence to aid dental practitioners, 
patients and policy makers in their decision making. As 
a pragmatic, multi-centre, randomised, open trial with 
blinded outcome evaluation, SCRiPT aims to eradicate 
the uncertainty that exists among dental practitioners 
when treating deep carious lesions by testing the inter-
ventions in the environment that they will most often be 
delivered in, dental primary care.
In order to ensure the results of this trial are widely 
applicable the geographical areas that are included in 
the SCRiPT Trial have been selected to yield a cross-sec-
tion of practices, operating in a range of different envi-
ronments and circumstances (e.g. high, middle or low 
income communities, rural and urban, method of remu-
neration for GDPs (capitation and fee for item of service 
or a banded payment system based on Units of Dental 
Activity (UDA)).
The study team is multidisciplinary and broad-based, 
and will be led by the teams at the Dental Health Ser-
vices Research Unit, Dundee and the Centre for Health-
care Randomised Trials in Aberdeen. This will ensure 
that whilst the trial design and conduct is of the highest 
standard, it remains practical and pragmatic at all times.
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